 Home > Active Ingredient News > Antitumor Therapy > Front Oncol: A retrospective study comparing nab-paclitaxel and docetaxel as neoadjuvant therapy in patients with HER2- breast cancer

Front Oncol: A retrospective study comparing nab-paclitaxel and docetaxel as neoadjuvant therapy in patients with HER2- breast cancer

 Last Update: 2022-01-23
 Source: Internet
 Author: User

Tags

source analysis

blockchain food safety

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

The efficacy of nab-paclitaxel as neoadjuvant chemotherapy in patients with HER2- breast cancer is unclear

breast cancer

This study retrospectively analyzed patients with HER2-negative breast cancer who underwent neoadjuvant therapy and surgery from May 2016 to April 2018

The study included 159 patients, including 79 in the nab-paclitaxel group and 80 in the docetaxel group

The ORRs of the albumin-paclitaxel group and the docetaxel group were 89.

Albumin - paclitaxel and docetaxel ORR group was 89.

Efficacy assessment

After subgroup analysis, triple-negative breast cancer (TNBC) patients had a higher pCR rate in the nab-paclitaxel group than in the docetaxel group (62.

Efficacy assessment subgroup analysis

After a median follow-up of 47 months, 33 of 159 patients (20.

Taken together, the study demonstrated a higher pCR rate with nab-paclitaxel compared with docetaxel, especially in patients with triple-negative or node-negative breast cancer

Studies have shown a higher pCR rate with nab-paclitaxel compared with docetaxel, especially in patients with triple-negative or node-negative breast cancer

Lv ZD, Song HM, Niu ZH, Nie G, Zheng S, Xu YY, Gong W and Wang HB (2022) Efficacy and Safety of Albumin-Bound Paclitaxel Compared to Docetaxel as Neoadjuvant Chemotherapy for HER2-Negative Breast Cancer.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Crocetin27876-94-4

CAS No.: 27876-94-4

$1-1.1/G FOB

Betulinic acid472-15-1

CAS No.: 472-15-1

$1-1.1/G FOB

1-(2-chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane 53-19-0

CAS No.: 53-19-0

Pharmacy Grade

$100/KG EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.